Subtitle
Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.
Subtitle
Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.
Proto therapy Time
December 2022
Executive summary
Published in the Red Journal, this study reported lymphopenia differences between IMRT and proton/carbon ion (PCIRT) for NSCLC. With data of 343 patients, this study reported that the PCIRT group was less likely to develop severe lymphopenia (SRL) (p <0.001). Compared with non-SRL group, SRL group showed significant association with poorer OS, with median survival time of 29.2 vs. 15.0 months (p = 0.046). Thoracic vertebra V5 (p =0.002) and aorta V5 (p =0.026) were identified as independent risk predictors of SRL after adding dosimetric parameters to the regression model
Top cancer treatments
Related contents
Proton Therapy Publication
April 2024
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
Proton Therapy Publication
March 2024
Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma - systematic review.
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
Proton Therapy Publication
August 2021
Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma
Proton Therapy Publication
July 2021
Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence
Proton Therapy Publication
June 20221
Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines.
Proton Therapy Publication
April 2021
Comparing second cancer risk for multiple radiotherapy modalities in survivors of Hodgkin lymphoma
Proton Therapy Publication
January 2021
Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory lymphoma: A PTCOG and PCG Collaboration.